Research Analysts Issue Forecasts for Cybin FY2026 Earnings

Cybin Inc. (NASDAQ:HELP) – Equities research analysts at HC Wainwright lowered their FY2026 earnings estimates for Cybin in a report released on Monday, March 2nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($4.42) for the year, down from their previous estimate of ($3.02). HC Wainwright has a “Buy” rating and a $95.00 price target on the stock. HC Wainwright also issued estimates for Cybin’s Q4 2026 earnings at ($1.04) EPS, FY2027 earnings at ($3.04) EPS, FY2028 earnings at ($1.49) EPS, FY2029 earnings at $0.87 EPS and FY2030 earnings at $4.18 EPS.

Separately, Jefferies Financial Group started coverage on Cybin in a research report on Monday, February 2nd. They issued a “buy” rating and a $22.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $58.50.

Cybin Trading Down 33.9%

NASDAQ:HELP opened at $5.64 on Thursday. Cybin has a twelve month low of $4.81 and a twelve month high of $9.83. The firm has a market cap of $282.39 million, a P/E ratio of -1.33 and a beta of 0.61.

Cybin (NASDAQ:HELP) last released its quarterly earnings data on Friday, February 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.19).

Trending Headlines about Cybin

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: HC Wainwright raised long-term earnings forecasts for FY2029 and FY2030 considerably (FY2029 to $0.87 and FY2030 to $4.18) and maintained a “Buy” rating with a $95 price target — a bullish long-term signal for growth expectations. HC Wainwright note (MarketBeat)
• Positive Sentiment: Media picked up the $95 price-target story (reiterating HC Wainwright’s outlook), which can support investor confidence despite near-term cuts. Price Target Raised to $95 (AmericanBankingNews)
• Neutral Sentiment: Helus Pharma reported positive Phase 2 topline results in generalized anxiety disorder — a peer/sector clinical update that may shift attention among psychedelics/psychedelic-adjacent investors but does not directly change Cybin’s data. Helus Phase 2 Topline (GlobeNewswire)
• Neutral Sentiment: Recent short-interest reports show “0 shares” and NaN changes — this appears to be a data/reporting error and should not be read as a credible signal about actual short activity or squeeze risk; treat these entries as unreliable until corrected.
• Negative Sentiment: HC Wainwright cut near-term forecasts materially — Q4 2026 EPS to ($1.04), FY2026 to ($4.42) and FY2027 to ($3.04) — which lowers near-term profitability expectations and likely pressured the stock during active trading. HC Wainwright note (MarketBeat)

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.